Antibody Fragments Market By Product Type (Fab, scFv, F(ab′)₂, Nanobodies, Others); By Application (Therapeutics, Diagnostics, Research); By End User (Pharmaceutical & Biotechnology Companies, Research Institutes, CROs, Diagnostic Laboratories); By Geography, Segment Revenue Estimation and Forecast, 2026–2032

Antibody Fragments Market: Smaller Binding Formats Expand Across Therapeutics, Diagnostics, and Engineered Biologics

The Global Antibody Fragments Market was valued at USD 8.06 billion in 2025 and is projected to reach approximately USD 11.34 billion by 2032, growing at a CAGR of 5.0%, according to Strategic Market Research.

 

The market covers Fab, Fab′, F(ab′)2, single-chain variable fragments, single-domain antibodies, VHH molecules, and other engineered antibody formats used across therapeutics, diagnostic testing, molecular imaging, research reagents, fusion proteins, and cell therapies.

 

Antibody fragments preserve the target-binding portion of a conventional antibody while excluding several larger structural regions present in full-length antibodies. A Fab fragment typically weighs around 50 kDa, an scFv generally ranges from 25–30 kDa, and a VHH domain is about 15 kDa, compared with approximately 150 kDa for a full-length IgG antibody. Because of their smaller size, these formats can penetrate dense tissues more effectively, enable higher concentrations in limited injection volumes, and support the design of engineered molecules that combine multiple binding domains.

 

Fragment Formats Divide Revenue Between Established Fab Products and Faster-Growing Engineered Platforms

Fab (Fragment Antigen-Binding): Cleaved using the enzyme papain, these "arms" of the antibody bind to a single antigen. ** The Fab segment was valued at approximately USD 3.06 billion in 2025, representing an estimated 38.0% market share, and is projected to reach USD 3.92 billion by 2032 at a CAGR of 3.6%. Its leading position reflects established therapeutic revenue from certolizumab pegol, ranibizumab, idarucizumab, and related Fab-based products, although biosimilar competition in ophthalmology limits the segment’s growth rate.

F(ab')2: Produced using pepsin, this divalent fragment contains two binding sites and retains hinge region integrity. ** The F(ab′)2 segment was valued at approximately USD 560 million in 2025 and is forecast to reach USD 750 million by 2032, expanding at a CAGR of 4.2%. Demand is concentrated in diagnostic reagents, imaging, neutralization studies, immunoassays, antivenoms, and research applications where divalent binding is required without the Fc-mediated activity of a complete antibody.

scFv (Single-Chain Variable Fragment): Engineered fragments linking the heavy and light chain variable regions with a flexible peptide linker, creating a highly versatile and small structure. ** The scFv segment generated an estimated USD 2.34 billion in 2025, equivalent to approximately 29.0% of the market, and is projected to reach USD 3.51 billion by 2032 at a CAGR of 6.0%. Growth is supported by the use of scFv domains in T-cell engagers, bispecific constructs, CAR-T therapies, fusion proteins, immunotoxins, diagnostic platforms, and molecular imaging products.

VHH (Single-Domain Antibodies): Derived from heavy-chain only antibodies found in camelids, these tiny fragments offer exceptional stability and tissue penetration. ** The VHH segment was valued at approximately USD 1.45 billion in 2025 and is forecast to reach USD 2.57 billion by 2032, recording the fastest fragment-type CAGR of 8.5%. VHH molecules are gaining commercial value through multivalent drugs, albumin-binding constructs, CAR-T products, bispecific proteins, inhaled candidates, diagnostic reagents, and fragment-based drug-discovery platforms.

Commercial adoption remains selective rather than universal. Full-length monoclonal antibodies continue to dominate approved biologics because their Fc region provides longer circulation and immune-system functions. Fragment formats become more attractive when developers need faster tissue penetration, rapid removal from circulation, limited Fc activity, compact molecular construction, or integration into T-cell engagers and cellular therapies.

These engineered formats benefit from the broader development infrastructure already established across antibody therapeutics and diagnostics. A 2025 scientific review identified 207 marketed antibody products worldwide and more than 1,500 therapeutic antibody products in clinical development. Standalone fragments remain a minority, but Fab, scFv, and VHH domains increasingly serve as functional components in bispecific proteins, immune-cell engagers, conjugates, and engineered cell therapies.

 

Four Fab Approvals Established the First Commercial Base

Four molecules have historically received FDA approval as Fab or Fab′ therapeutics without a complete Fc region: abciximab, ranibizumab, certolizumab pegol, and idarucizumab. Their indications show where a compact binding format has delivered clear clinical and commercial value.

Abciximab, approved in 1994 as ReoPro, was developed to prevent platelet aggregation during coronary interventions. Ranibizumab, approved as Lucentis in 2006, established Fab fragments as a major ophthalmology platform by blocking VEGF inside the eye. Certolizumab pegol, approved as Cimzia in 2008, added polyethylene glycol to a Fab′ fragment to extend systemic exposure for inflammatory diseases. Idarucizumab, approved as Praxbind in 2015, uses a Fab fragment to rapidly neutralize the anticoagulant dabigatran during life-threatening bleeding or urgent procedures.

These products also show that short circulation time is not always a disadvantage. Rapid removal can be valuable in emergency reversal agents and diagnostic imaging, where prolonged activity or background signal is undesirable. Chronic inflammatory diseases require the opposite approach, prompting developers to use PEGylation, albumin-binding domains, multimerization, or other half-life extension methods.

Certolizumab pegol remains one of the strongest commercial validations of the Fab format. UCB reported approximately EUR 1.95 billion in Cimzia sales during 2025, making it the company’s second-largest product. Its scale indicates that a fragment-based medicine can remain commercially relevant for many years when the format is matched to a large disease population and supported by dosing technology that overcomes rapid clearance.

 

Ranibizumab Biosimilars Reshape Ophthalmology Revenue

Ophthalmology remains an important antibody-fragment application because small molecules can be delivered at high concentrations within the limited volume available for intravitreal injections. The CDC estimated that 19.8 million Americans aged 40 years and older were living with age-related macular degeneration in 2019, including approximately 1.5 million people with late-stage disease. This large and ageing patient population continues to support demand for anti-VEGF therapies.

Ranibizumab created a substantial commercial market, but its revenue structure is moving from originator exclusivity toward biosimilar competition. The FDA had already approved Byooviz and Cimerli before adding Nufymco in December 2025 and Ranluspec in June 2026 as additional Lucentis biosimilars. Each approval expands purchasing options for health systems and strengthens payer leverage over pricing.

Roche grouped Lucentis among its loss-of-exclusivity products in 2025. Fragment suppliers entering mature indications will increasingly compete on manufacturing consistency, reimbursement access, and contracting rather than molecular novelty alone.

Brolucizumab, marketed as Beovu, introduced another ophthalmic fragment format. FDA labeling identifies it as a humanized scFv antibody fragment with a molecular weight of approximately 26 kDa, produced in Escherichia coli. Its compact structure permits a high molar dose in a small injection volume, although safety monitoring and competition from established anti-VEGF products continue to influence adoption.

 

scFv Formats Generate Revenue Through T-Cell Engagement

Standalone scFv medicines remain uncommon, but scFv domains are widely used inside bispecific proteins, immune-cell engagers, immunotoxins, imaging agents, and CAR-T therapies. Scientific reviews estimate that scFv formats account for close to 35% of antibody fragments evaluated in clinical trials, with oncology receiving the largest share of development attention.

Blinatumomab provides the clearest commercial example. The molecule contains two linked single-chain binding regions that connect CD19-positive cancer cells with CD3-positive T cells. In June 2024, the FDA expanded Blincyto into the consolidation phase of chemotherapy for adults and children with CD19-positive, Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

The broader indication translated into higher utilization. Amgen reported USD 1.56 billion in Blincyto sales during 2025, an increase of approximately 28% over the previous year. Sales reached USD 370 million in the first quarter of 2025 alone, up 52% year over year, primarily because of volume growth. Fragment-based T-cell engagement has therefore moved from a specialist scientific format into a billion-dollar commercial category.

Tebentafusp, marketed as Kimmtrak, combines a soluble T-cell receptor with an anti-CD3 scFv domain. The FDA approved it in 2022 for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma. Immunocore reported USD 400 million in Kimmtrak sales in 2025, compared with USD 310 million in 2024, and had launched the product in 30 countries by the end of 2025.

Blinatumomab and tebentafusp also reveal a commercial limitation: short half-life may require frequent or continuous administration. Reducing this treatment burden could widen adoption.

 

VHH Platforms Turn Single Domains Into Multispecific Products

VHH molecules, frequently called nanobodies, are among the smallest naturally derived antibody-binding domains. Their compact structure allows developers to link several units within one molecule, attach them to albumin-binding domains, incorporate them into cell therapies, or explore delivery routes that are difficult for conventional antibodies.

A 2025 peer-reviewed assessment identified five globally marketed therapies containing VHH-based binding domains: caplacizumab, netakimab, envafolimab, ozoralizumab, and ciltacabtagene autoleucel. These products include a bivalent VHH medicine, VHH-Fc proteins, a trivalent anti-TNF construct, an IgG-like antibody containing a VHH domain, and a CAR-T therapy with two BCMA-binding VHH domains. Approval totals therefore depend on whether the market definition includes only standalone fragments or also fragment-derived fusion proteins and cell therapies.

Caplacizumab, marketed as Cablivi, was the first VHH-based medicine approved by the FDA. In January 2026, the agency expanded its indication to patients aged 12 years and older with acquired thrombotic thrombocytopenic purpura, widening the addressable treatment population.

Ciltacabtagene autoleucel, marketed as Carvykti, demonstrates how VHH technology can generate value inside a cellular therapy rather than as an injected antibody product. Its CAR contains two VHH-derived BCMA-binding regions. Legend Biotech reported approximately USD 1.9 billion in Carvykti net trade sales during 2025, compared with about USD 963 million in 2024. More than 10,000 patients had been treated, and the product was available at 294 sites worldwide by March 2026.

Sanofi continues to develop multivalent Nanobody molecules by linking several fragments in one construct, while Alloy Therapeutics and the Institute for Protein Innovation announced a 2026 collaboration to create humanized VHH libraries for bispecific and multispecific discovery. These investments position VHH technology as a platform for licensing, target discovery, and engineered biologics rather than a narrow class of standalone drugs.

 

Oncology Pulls Fragment Engineering Into Larger Commercial Markets

Oncology is the largest development opportunity because compact binding domains can redirect immune cells, carry radioactive or cytotoxic payloads, recognize more than one tumor target, or improve access to solid-tumor tissue.

The global cancer burden supports continued investment. IARC estimated approximately 20 million new cancer cases and 9.7 million cancer deaths in 2022. Annual incidence is projected to reach around 35 million cases by 2050 as populations grow and age.

Commercial evidence from Blincyto, Kimmtrak, and Carvykti has reduced the perceived platform risk attached to fragment-derived cancer therapies. Developers can now point to approved products across hematologic malignancies, solid tumors, rare ocular cancers, and cell therapy. The next wave includes multispecific T-cell engagers, fragment-drug conjugates, cytokine fusions, radiolabeled fragments, and gene therapies that produce fragment-based molecules inside the patient.

Clinical programs are also testing fragment formats in imaging, where faster blood clearance may improve tumor contrast. Oncology programs still face risks from cytokine release, target-related toxicity, immunogenicity, and complex dosing. Commercial value depends on whether the format improves outcomes or delivery compared with established therapies.

 

Autoimmune Diseases Sustain Demand for Half-Life-Extended Fragments

Autoimmune and inflammatory diseases provide a second major commercial base. WHO estimates that approximately 18 million people worldwide were living with rheumatoid arthritis in 2019, while the wider population affected by musculoskeletal conditions exceeded 1.7 billion. Long treatment duration and recurring biologic use create substantial lifetime demand, but chronic indications require convenient dosing and sustained drug exposure.

Cimzia addresses the short half-life of an unmodified Fab′ through PEGylation. Ozoralizumab uses two anti-TNF VHH domains and an albumin-binding VHH to prolong circulation, while sonelokimab combines two IL-17-binding domains with an albumin-binding domain. MoonLake advanced sonelokimab into Phase 3 studies in psoriatic arthritis and hidradenitis suppurativa, demonstrating continued investment in VHH-based inflammatory-disease platforms.

Competition remains intense. Fragment products must compete against established monoclonal antibodies, biosimilars, oral small molecules, and long-acting injectable biologics. Better tissue access alone is unlikely to secure premium pricing unless accompanied by longer remission, faster response, improved safety, or lower treatment burden.

 

Diagnostics and Research Products Broaden the Revenue Base

Therapeutic products account for the most visible revenues, but antibody fragments also serve diagnostic laboratories, academic institutions, pharmaceutical developers, imaging companies, and reagent suppliers. Fc-free formats can reduce unwanted interactions in assays, improve access to tightly packed molecular targets, and support rapid removal of unbound imaging agents.

Fab and F(ab′)2 reagents are used in immunoassays, flow cytometry, histology, infectious-disease research, neutralization studies, and conjugated detection systems. scFv and VHH products are increasingly used in biosensors, structural biology, target validation, intracellular research, and recombinant diagnostic development.

Databases such as SAbDab, Thera-SAbDab, and NCBI IgBLAST support discovery by organizing structural and sequence information, reducing early screening work and helping developers identify design risks.

Diagnostic and research suppliers compete on clone validation, reproducibility, conjugation options, recombinant production, application-specific testing, and delivery time. Strong validation can command higher prices because assay developers place greater value on consistency and reduced background than on production volume alone.

 

Microbial Production Lowers Some Costs but Does Not Remove Development Risk

Many scFv and VHH products can be produced in microbial systems because they do not require the Fc glycosylation needed by conventional antibodies. Brolucizumab is manufactured in E. coli, creating a potential cost and scale advantage over mammalian-cell production. Microbial expression can also shorten development cycles for research reagents and early clinical material.

The advantage does not apply equally to every fragment. Idarucizumab is produced in Chinese hamster ovary cells, while some fusion proteins, conjugated fragments, and multispecific constructs require complex refolding, purification, linker control, potency testing, or sterile filling.

Manufacturers must control aggregation, incorrect chain pairing, chemical instability, loss of binding activity, rapid renal clearance, and immunogenicity. Half-life extension can solve one problem while adding production and regulatory complexity. CDMOs and specialist service providers can gain share by offering fragment-specific expression screening, purification, conjugation, developability analysis, pharmacokinetic testing, and formulation support.

 

North America Leads Commercialization While Europe and Asia Broaden the Format Mix

North America remains the leading commercialization region because of its concentration of biotechnology companies, oncology programs, FDA approvals, research funding, and premium-priced biologics. Immunocore generated approximately USD 257 million of Kimmtrak’s USD 400 million 2025 revenue in the United States, while Blincyto and Carvykti provide further evidence of strong U.S. adoption.

Europe combines established products with antibody engineering and manufacturing expertise, led by UCB’s Cimzia franchise, Sanofi’s Nanobody platform, and Immunocore’s Kimmtrak expansion.

Asia-Pacific is gaining importance through local approvals, trials, recombinant manufacturing, and platform development. China approved envafolimab, while Japan approved ozoralizumab, and regional developers are integrating scFv and VHH domains into bispecific antibodies and CAR-T products.

 

Competitive Positioning Is Dividing Between Product Owners and Platform Suppliers

The competitive landscape includes companies with marketed fragment-based medicines, developers building new molecular formats, and suppliers supporting discovery and manufacturing.

UCB holds one of the largest standalone Fab franchises through Cimzia. Amgen has established a leading scFv-derived oncology product through Blincyto. Roche and Genentech created the commercial Fab ophthalmology market with Lucentis but now face growing biosimilar competition. Novartis competes through Beovu, while Immunocore has commercialized a TCR-scFv fusion platform through Kimmtrak.

Sanofi owns Cablivi and continues to develop multivalent Nanobody constructs. Johnson & Johnson and Legend Biotech have demonstrated the value of VHH binding domains inside cell therapy through Carvykti. Boehringer Ingelheim occupies a specialized emergency-care position with Praxbind, while MoonLake is testing whether VHH-based medicines can compete in large inflammatory indications.

 

Market Outlook: Revenue Will Follow Modality Fit, Not Molecular Size

The antibody fragments market will not expand by replacing full-length monoclonal antibodies across every indication. Revenue growth will come from clinical situations where smaller or modular binding formats solve a defined treatment, delivery, or manufacturing problem.

Fab products will retain an established position in inflammatory disease, ophthalmology, and emergency medicine, although ranibizumab biosimilars will place pressure on originator pricing. scFv formats will gain greater value through T-cell engagers, fusion proteins, CAR constructs, and targeted imaging rather than through large numbers of standalone products. VHH molecules offer broad engineering flexibility for multispecific medicines, albumin-binding constructs, cell therapies, inhaled products, and fragment-drug conjugates.

Commercial proof has moved beyond isolated approvals. Blincyto, Cimzia, Kimmtrak, and Carvykti demonstrate billion-dollar or rapidly scaling revenue opportunities across several fragment architectures. Their success reflects more than molecular size: each product has a distinct target, delivery strategy, dosing model, clinical endpoint, and reimbursement pathway.

 

Antibody Fragments Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 8.06 Billion
Revenue Forecast in 2032	USD 11.34 Billion
Overall Growth Rate	CAGR of 5.0% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Fab, Fab′, F(ab′)2, Single-Chain Variable Fragments (scFv), Single-Domain Antibodies / VHH, Others
By Application	Therapeutics, Diagnostics, Research Reagents, Molecular Imaging, Fusion Proteins, Cell Therapies
By End User	Pharmaceutical & Biotechnology Companies, Research Institutes, Contract Research Organizations (CROs), Diagnostic Laboratories, Academic Institutions
By Geography	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, Switzerland, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising adoption of engineered biologics, expansion of bispecific antibody and T-cell engager platforms, increasing demand for targeted oncology therapies, growth of fragment-based diagnostics, advances in antibody engineering technologies, and rising investment in next-generation biologics
Customization Option	Available upon request